TNFRSF9 and neoplasm: These results demonstrate that the TRACER approach with MazNP effectively enhanced tumor-specific accumulation of anti–4-1BB, while reducing accumulation in nontumor tissues, potentially minimizing the systemic toxicities associated with anti–4-1BB therapy.